Stifel Lowers Price Target on Outset Medical, Inc. (OM) to $8, Maintains Buy Rating

Company Overview - Outset Medical, Inc. (NASDAQ:OM) was founded in 2003 and is headquartered in San Jose, California, focusing on transforming dialysis through innovative technology and North American manufacturing operations [4] Financial Performance - In Q3 2025, Outset Medical reported revenue of $29.4 million, reflecting a 3% year-over-year increase [3] - The company raised its 2025 revenue guidance to a range of $115 million to $120 million [3] - Tablo console sales increased by 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20% [3] Analyst Insights - Stifel analyst Rick Wise lowered the price target on Outset Medical to $8 from $14 while maintaining a Buy rating, indicating near-term pressures in MedTech following 2025, but a constructive outlook for the sector overall in 2026 [1]